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Abstract 
Background 
Data on left atrial/left atrial appendage (LA/LAA) thrombus resolution after nonvitamin K 
antagonist (VKA) oral anticoagulant (NOAC) treatment are scarce. The primary objective of X-
TRA was to explore the use of rivaroxaban for the resolution of LA/LAA thrombi in patients with 
nonvalvular atrial fibrillation (AF) or atrial flutter, with the CLOT-AF registry providing 
retrospective data after standard-of-care therapy in this setting. 
Methods 
X-TRA was a prospective, single-arm, open-label, multicenter study that investigated 
rivaroxaban treatment for 6 weeks for LA/LAA thrombus resolution in patients with nonvalvular 
AF or atrial flutter and LA/LAA thrombus confirmed at baseline on a transesophageal 
echocardiogram (TEE). CLOT-AF retrospectively collected thrombus-related patient outcome 
data after standard-of-care anticoagulant treatment for 3-12 weeks in patients with nonvalvular 
AF or atrial flutter who had LA/LAA thrombi on TEE recorded in their medical file. 
Results 
In X-TRA, patients were predominantly (95.0%) from Eastern European countries. The 
adjudicated thrombus resolution rate was 41.5% (22/53 modified intention-to-treat [mITT] 
patients; 95% confidence interval [CI] 28.1-55.9%) based on central TEE assessments. 
Resolved or reduced thrombus was evident in 60.4% (32/53 mITT patients; 95% CI 46.0-73.6%) 
of patients. In CLOT-AF, the reported thrombus resolution rate was 62.5% (60/96 mITT patients; 
95% CI 52.0-72.2%), and appeared better in Western European countries (34/50; 68.0%) than 
Eastern European countries (26/46; 56.5%). 
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Conclusion 
X-TRA is the first prospective, multicenter study examining LA/LAA thrombus resolution with 
a NOAC in VKA-naïve patients or in patients with suboptimal VKA therapy. Rivaroxaban could 
be a potential option for the treatment of LA/LAA thrombi. 
 
Word count: 246/250 
 
Trial registration numbers: ClinicalTrials.gov: NCT01839357 (X-TRA); ClinicalTrials.gov: 
NCT01928979 (CLOT-AF). 
 
Keywords 
Anticoagulant; Atrial fibrillation; Left atrial appendage thrombus resolution; Rivaroxaban; 
Transesophageal echocardiography 
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Introduction 
Atrial fibrillation (AF) predisposes patients to the development of atrial thrombi, most often in 
the left atrial (LA) appendage (LAA). LAA thrombi are the dominant source of embolism (>90%) 
in patients with nonvalvular AF,1,2 and LA/LAA thrombi are identified in ~10% of patients with 
AF.3 
The use of a transesophageal echocardiogram (TEE) is an established standard for 
detecting the presence of LA/LAA thrombi.4–6 If a LA/LAA thrombus is detected on a TEE, 
current guidelines1,7 recommend vitamin K antagonist (VKA) treatment with a therapeutic 
international normalized ratio (INR) of 2.0 to 3.0 for at least 3 weeks, and a follow-up TEE to 
ensure thrombus resolution prior to interventions such as cardioversion. However, reported 
thrombus resolution rates with VKAs vary between approximately 50% and 90% after a median 
of 4 weeks’ treatment.8–13 Reasons for this wide range of resolution rates include differences in 
patient populations (e.g. with or without the inclusion of valvular AF;14 first diagnosed or 
persistent AF) and anticoagulation strategies/treatment durations, or the use of imaging 
strategies evaluated in relatively small observational studies.8–11,15,16 Data on LA/LAA thrombus 
resolution after non-VKA oral anticoagulant (NOAC)17 treatment are scarce and largely comprise 
case reports, which generally indicate favorable outcomes.18–22 
The primary objective of the prospective X-TRA study was to explore the use of the NOAC 
rivaroxaban for the resolution of LA/LAA thrombi in patients with nonvalvular AF or atrial flutter 
who had a TEE-confirmed LA/LAA thrombus. The objective of the CLOT-AF registry was to 
provide retrospective thrombus-related patient outcome data after standard-of-care 
anticoagulant treatment in patients with nonvalvular AF or atrial flutter who had TEE-
documented LA/LAA thrombi. 
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Methods 
Study design and patient population 
X-TRA study 
In brief, the X-TRA study (ClinicalTrials.gov identifier NCT01839357) was a prospective, 
interventional, single-arm, open-label, multicenter study, as described previously.23 X-TRA was 
designed to explore once-daily (od) rivaroxaban (20 mg od, or 15 mg od in patients with 
creatinine clearance 15–49 mL/min) for the resolution of LA/LAA thrombi in patients with 
nonvalvular AF or atrial flutter and LA/LAA thrombus confirmed using a TEE at baseline. Eligible 
patients had to be VKA/NOAC naïve or untreated within 1 month prior to signing the informed 
consent form (treatment of up to 72 h with VKA, heparin, or a low molecular weight heparin was 
allowed before the start of rivaroxaban); or, following an amendment, VKA-pretreated but with 
suboptimal or ineffective INR levels (i.e. < 2.0, documented with at least two consecutive 
measurements that were at least 24 h apart) within the last 6 weeks. The primary endpoint was 
the complete LA/LAA thrombus resolution rate on the centrally adjudicated end-of-treatment 
(EOT) TEE after 6 weeks’ treatment with rivaroxaban. The secondary objectives were centrally 
adjudicated categories of thrombus outcome (resolved, reduced, unchanged, larger, or new) 
confirmed on TEE at EOT; incidence of the composite of stroke and noncentral nervous system 
systemic embolism at EOT and during follow-up; and incidence of all bleeding events (major 
bleeding according to International Society on Thrombosis and Haemostasis [ISTH] criteria24 
and nonmajor bleeding) at EOT and during follow-up. 
CLOT-AF registry 
In brief, the CLOT-AF registry (ClinicalTrials.gov identifier NCT01928979) retrospectively 
collected thrombus-related patient outcome data after standard-of-care anticoagulant treatment 
in patients with nonvalvular AF or atrial flutter who had LA/LAA thrombi on a TEE recorded in 
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their medical file.23 The primary outcome of interest was the reported thrombus resolution rate 
confirmed on a TEE after 3-12 weeks of anticoagulation therapy based on the routine practice of 
the participating centers without central adjudication. Secondary endpoints were rates of stroke 
or noncentral nervous system systemic thromboembolism and all bleeding events (major [ISTH 
criteria],24 nonmajor, unknown severity). 
Thrombus assessment 
X-TRA study 
To ensure an objective assessment, TEE images were assessed centrally by independent 
adjudicators in a blinded fashion without knowledge of whether an image was pre- or post-
treatment. The adjudicators were specialists in cardiology with a specific interest in TEE who 
were not otherwise involved in the study. 
Each TEE was reviewed by two adjudicators. Both had to agree in their assessment, i.e. 
absence of a thrombus or degree of thrombus burden. A third adjudicator performed the final 
judgment if their assessment differed by > 1 mm for thrombi with an average thrombus diameter 
≤ 10 mm, by > 2 mm for thrombi with an average diameter > 10 to ≤ 20 mm, or by > 3 mm for 
thrombi with an average diameter > 20 mm. 
Pre-defined thrombus outcome criteria were as follows: "resolved" if no thrombus was 
detectable on the EOT TEE and "reduced"/"larger" if the thrombus was smaller/larger than at 
baseline (dependent on thrombus size). To qualify as a reduction or an increase compared with 
baseline, the thrombus size had to be reduced/enlarged by >1 mm for thrombi <10 mm in 
diameter at baseline, by > 2 mm for thrombi of 10 to ≤ 20 mm in diameter at baseline, and by 
> 3 mm for thrombi > 20 mm in diameter at baseline. If the change was < 1 mm, the thrombus 
outcome was assessed as "unchanged". A "new" thrombus was one that had not been present 
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on the baseline TEE. Patients were categorized according to the most severe category into 
which any thrombus fell. 
CLOT-AF registry 
The image assessment was used as recorded in the patients' medical file without 
adjudication, in contrast to X-TRA. 
Ethical considerations 
For both studies, approval from the appropriate Independent Ethics Committee/Institutional 
Review Board was obtained for all participating centers before the start of the study, in 
accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice 
(GCP) and local laws, regulations, and organizations, as applicable. Informed consent was 
obtained from all patients; for the CLOT-AF registry, informed consent from a primary relative 
was also accepted if allowed by local regulations. 
Statistical evaluation 
In both studies, statistical analyses were of an explorative and descriptive nature. Mean 
values were calculated based on the number of available data. Frequency distributions include a 
category for missing data, if applicable. The studies did not aim to confirm or refute any pre-
defined hypotheses. Statistical evaluations were performed using the software package SAS 
release 9.4 (SAS Institute Inc., Cary, NC USA). 
X-TRA study 
The sample size was estimated based on the expected presence of LA/LAA thrombi 
detected on a TEE in the participating study sites and aimed to enroll 60 patients. Enrolled 
patients were analyzed on an intention-to-treat (ITT) basis. Patients with complete data on 
baseline and EOT TEEs were included in the modified ITT (mITT) population. The primary 
analysis evaluated the thrombus outcome in the mITT population. Exact (Clopper–Pearson) 95% 
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confidence intervals (CIs) for the probability of complete thrombus resolution in the LA/LAA were 
calculated. As a sensitivity analysis (worst-case scenario applied), thrombus resolution was 
calculated based on the ITT population, considering patients without an evaluable EOT TEE as 
still having a thrombus. In addition, exact (Clopper–Pearson) 95% CIs were calculated for the 
combined category of resolved/reduced. 
CLOT-AF registry 
No sample size was calculated, but at the planned 15 to 20 study sites the inclusion of 
~150 patients was expected. The ITT population was the number of eligible and enrolled 
patients, and the mITT population was the number of patients with baseline and EOT TEEs. The 
primary analysis evaluated the thrombus resolution rate using exact (Clopper–Pearson) 95% CIs 
in the mITT patient population. 
As best-/worst-case analyses, thrombus resolution was calculated based on the ITT 
population, considering patients without an evaluable EOT TEE as having resolved 
thrombus/still having a thrombus. 
 
The studies were funded by Bayer Pharma AG. The authors are responsible for the design and 
conduct of the studies and all study analyses, the drafting of the paper and its final contents. 
Results 
Disposition of patients, demographics, and baseline characteristics 
X-TRA study 
The X-TRA study was conducted at 17 study centers in 7 countries between August 2013 
and December 2014. A total of 60 patients were included in the ITT population. The mITT 
population with complete TEE data encompassed 53 patients: 7 patients were excluded from the 
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mITT population, of these, 4 patients had no thrombus at baseline TEE as adjudicated (1 patient 
withdrew from the study because of an adverse event), and 3 patients had no end-of-treatment 
TEE (1 patient died from acute heart failure, 1 patient emigrated to another country because of a 
war, and 1 patient was hospitalized for heart transplantation). The patient disposition is 
summarized in Figure 1. No patients were lost to follow-up. 
 
[Insert Figure 1 here – 1.5 column width] 
 
Almost all patients (95.0%) were from Eastern European countries, half were male, and 
mean patient age was 70 years, with the majority of patients (61.7%) aged 65 years or older. 
Mean bodyweight was 85 kg, and 48.3% of patients had a body mass index of ≥ 30 kg/m2. 
Approximately three-quarters of patients (76.6%) presented with persistent, long-standing 
persistent, or permanent AF. The median CHADS2 and CHA2DS2-VASc scores were 2 and 4, 
respectively; most patients were in the high-risk category – 66.7% of patients had a CHADS2, 
score ≥2.0 and 83.3% had a CHA2DS2-VASc score of ≥2.0. The most common risk factors were 
hypertension (81.7%), heart failure (55.0%), prior stroke/transient ischemic attack (18.3%), and 
diabetes (15.0%). Approximately three-quarters of the patients (76.7%) had no prior VKA or 
NOAC treatment (Table I, ITT). These patients were VKA/NOAC naïve or untreated according to 
the original study design before the last amendment of the protocol. Results of the TEE analysis 
are summarized in Supplementary Table I. According to the central TEE assessment, a total of 
55 LAA thrombi (mean values ± standard deviation: diameter 15 ± 7.5 mm, area 130.8 ± 108.6 
mm2) and three LA thrombi (mean values ± standard deviation diameter 18.7 ± 3.8 mm, area 
162.7 ± 72.6 mm2) were detected on TEE in 53 patients (mITT population), in which 5 patients 
had two thrombi (all in the LAA except for one LA thrombus). 
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Table I Demographic data and baseline characteristics of subjects enrolled in the X-TRA study 
and the CLOT-AF registry (ITT population) 
 Prospective X-TRA study Retrospective CLOT-AF 
registry 
 (n = 60) (n = 156) 
Region, n (%)   
Eastern Europe 57 (95.0) 82 (52.6) 
Western Europe 3 (5.0) 74 (47.4) 
Sex: male, n (%) 30 (50.0) 103 (66.0) 
Age, years, mean ± SD 69.6 ± 11.0 67.7 ± 9.6 
Age category, years, n (%)   
< 65 23 (38.3) 59 (37.8) 
65-74 13 (21.7) 57 (36.5) 
≥ 75 24 (40.0) 40 (25.6) 
Bodyweight, kg, mean ± SD 85.1 ± 17.6 81.7 ± 15.5 
BMI, kg/m
2
, mean ± SD 30.7 ± 6.0 27.8 ± 4.9 
BMI, kg/m
2
, n (%)   
< 25 8 (13.3) 32 (20.5) 
25-< 30 23 (38.3) 56 (35.9) 
≥ 30 29 (48.3) 39 (25.0) 
Missing – 29 (18.6) 
CrCl, mL/min, n (%)* 
30-< 50 
≥ 50 
Not recorded 
 
11 (18.3) 
49 (81.7) 
– 
 
15 (9.6) 
96 (61.5) 
45 (28.8) 
Medical history, n (%)   
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 Prospective X-TRA study Retrospective CLOT-AF 
registry 
 (n = 60) (n = 156) 
Presence of any risk factor 56 (93.3) 144 (92.3) 
Arterial hypertension 49 (81.7) 127 (81.4) 
Congestive heart failure/left 
ventricular failure 
33 (55.0) 75 (48.1) 
Diabetes mellitus 9 (15.0) 35 (22.4) 
Myocardial infarction 5 (8.3) 26 (16.7) 
Stroke/transient ischemic attack 11 (18.3) 16 (10.3) 
Peripheral artery disease 5 (8.3) 12 (7.7) 
Thromboembolism/non-CNS 
systemic embolism 
2 (3.3) 9 (5.8) 
Complex aortic plaque 3 (5.0) 9 (5.8) 
Referral diagnosis, n (%)   
AF 57 (95.0) 151 (96.8) 
First-diagnosed 4 (6.7) 13 (8.3) 
Paroxysmal 2 (3.3) 19 (12.2) 
Persistent/long-standing persistent 32 (53.3) 63 (40.4) 
Permanent 14 (23.3) 25 (16.0) 
Missing 5 (8.3) 35 (22.4) 
Atrial flutter, alone
†
 3 (5.0) 5 (3.2) 
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 Prospective X-TRA study Retrospective CLOT-AF 
registry 
 (n = 60) (n = 156) 
CHADS2 score
‡
,
 
median 2.0 2.0 
CHADS2 category, n (%) 
0 
1 
≥ 2 
Missing 
 
3 (5.0) 
17 (28.3) 
40 (66.7) 
– 
 
4 (2.6) 
30 (19.2) 
72 (46.2) 
50 (32.1) 
CHA2DS2-VASc score
‡
;
 
median 4.0 3.0 
CHA2DS2-VASc category, n (%)   
0 (or 1, if female only) 2 (3.3) 1 (0.6) 
1 (except for female alone) 8 (13.3) 12 (7.7) 
≥ 2 50 (83.3) 91 (58.3) 
Missing – 52 (33.3) 
No prior use of VKA
§
/NOAC, n (%) 46 (76.7) 87 (55.8) 
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CNS, central nervous system; CrCl: 
creatinine clearance; ITT, intention-to-treat; NOAC, nonvitamin K antagonist oral anticoagulant; 
SD, standard deviation. 
*In X-TRA no patient with CrCl < 15 mL/min was enrolled. In CLOT-AF the CrCl categories: < 50 
mL/min, ≥ 50-80 mL/min, and > 80 mL/min. †Both AF and atrial flutter were recorded for 6 ITT 
patients in the X-TRA study and for 14 ITT patients in the CLOT-AF registry. ‡High number of 
missing records in case of CLOT-AF (see number missing in the presentation by category). §For 
CLOT-AF numbers refer to "no prior use of VKA", because in the participating countries most 
NOACs were not available during the observation period.  
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CLOT-AF registry 
Medical records at the study sites encompassed the period from January 2010 to February 
2013. Only the extension of the originally planned screening period from January 2011 to 
January 2010 allowed us to meet the target number of ~150 patients. The retrospective CLOT-
AF registry included 156 patients in the ITT population at 23 centers of the same 7 countries as 
in X-TRA. The mITT population with complete TEE data encompassed 96 patients (Figure 1). 
In contrast to the X-TRA study, patient numbers were balanced between Eastern (52.6%) 
and Western (47.4%) European countries. In total, 66.0% of the patients were male, and mean 
patient age was 68 years; 62.0% were aged 65 years or older. Mean bodyweight was 82 kg, and 
25.0% of patients had a body mass index of ≥ 30 kg/m2. 
The number of patients with persistent, long-standing persistent, or permanent AF was 
56.4%; information on the type of AF was missing for 22.4% of patients. The median CHADS2 
and CHA2DS2-VASc scores were 2.0 and 3.0, respectively. The most common risk factors were 
hypertension (81.4%), heart failure (48.1%), diabetes (22.4%), and myocardial infarction 
(16.7%); prior stroke/transient ischemic attack was recorded in 10.3% of patients (Table I, ITT). 
Before the start of the observation period, 55.8% of patients were VKA-naïve. Owing to the 
retrospective nature of this registry, only limited information on prior VKA use and INR 
monitoring was available. 
Treatment in X-TRA and observation in CLOT-AF 
X-TRA study 
The majority of the ITT patients (81.7%) received oral rivaroxaban 20 mg od; 18.3% with 
moderate-to-severe renal impairment received the lower dose of 15 mg od. Mean compliance 
calculated by tablet accountability was almost 100%. The mean treatment duration was 46 days 
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(ITT, mITT). Most patients had their EOT TEE performed within the recommended timeframe, 
after 6-8 weeks of rivaroxaban treatment (85.0% ITT, 90.6% mITT).  
CLOT-AF registry 
A total of 148/156 (94.9%) of patients had a record of any anticoagulation treatment. In most 
patients the anticoagulant treatment was a VKA (127/156 patients, 81.4%), either prescribed 
alone or in combination with another treatment (most often molecular weight heparin or 
unfractionated heparin. For those treated with a VKA, the types of VKA used included 
acenocoumarol in 45 patients (28.8%), warfarin in 29 patients (18.6%), phenprocoumon in 27 
patients (17.3%), fluindione in 25 patients (16.0%), and one patient with dicoumarol (0.6%). 
The observation period started with the diagnosis of an LA/LAA thrombus on the baseline 
TEE. In the mITT population, 83.3% of patients had the protocol-defined observation period of 3-
12 weeks; for 5 patients (5.2%) this period was < 3 weeks or unknown, and for 11 patients 
(11.5%) it was > 12 weeks (up to 6 months). 
Thrombus resolution rates 
X-TRA study 
In the X-TRA study, the thrombus resolution rate was 41.5% by patient (22/53 mITT 
patients; 95% CI 28.1-55.9%) based on central TEE assessments (Table II). Resolved or 
reduced thrombus was evident in 60.4% (32/53 mITT patients; 95% CI 46.0-73.6%) of patients 
(Table II). Thrombus resolution rates in subgroups are presented in Supplementary Table II. 
Patients with thrombus resolution tended to have lower thromboembolic risk scores 
(CHADS2/CHA2DS2-VASc) and to be older (aged > 75 years). 
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Table II Resolution rates of LA/LAA thrombi 
 Evaluation set Total N Thrombus resolution 95% CI 
   n thrombus resolved %  
Prospective X-TRA study      
Complete thrombus resolution (assessed by 
blinded adjudicators)* 
mITT 53 22 41.5 28.1-55.9 
Complete thrombus resolution (assessed by 
blinded adjudicators), worst-case scenario 
considering subjects without EOT TEE as 
non-resolved 
ITT 60 22 36.7 24.6-50.1 
Resolved or reduced thrombus (assessed 
by blinded adjudicators)
†
 
mITT 53 32 60.4 46.0-73.6 
Retrospective CLOT-AF registry      
Complete thrombus resolution mITT 96 60 62.5 52.0-72.2 
Complete thrombus resolution by region      
Eastern Europe mITT 46 26 56.5 41.1-71.1 
Western Europe mITT 50 34 68.0 53.3-80.5 
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 Evaluation set Total N Thrombus resolution 95% CI 
   n thrombus resolved %  
Complete thrombus resolution, worst-case 
scenario considering subjects without EOT 
TEE as non-resolved 
ITT 156 60 38.5 30.8-46.6 
Complete thrombus resolution, best-case 
scenario considering subjects without EOT 
TEE as resolved 
ITT 156 120 76.9 69.5-83.3 
Abbreviations: CI, confidence interval; EOT, end of treatment; ITT, intention-to-treat; mITT, modified intention-to-treat; TEE, 
transesophageal echocardiogram. 
*This includes 2 patients who had two thrombi each. Both thrombi were resolved in each case. †In 12 patients (22.6%) thrombi were 
larger and in another 9 patients (17.0%) thrombi were found unchanged (blinded central assessment); no patients had a new thrombus. 
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The resolution rate by individual thrombus outcome was 46.6% (27/58, mITT). With regard 
to the 5 patients with two thrombi each at baseline, at EOT 2 patients had both their LAA thrombi 
resolved, 2 patients had one LAA thrombus resolved and one thrombus unchanged (LAA in 1 
patient and LA in 1 patient), and 1 patient had one LAA thrombus resolved and one enlarged 
(maximum area 50-> 51 mm2, maximum diameter 6-> 10 mm). Of the 2 patients with a single LA 
thrombus at baseline, in 1 patient the LA thrombus was resolved and in the other there was no 
LA thrombus at EOT, but an LAA thrombus appeared. 
CLOT-AF registry 
In the CLOT-AF registry, the recorded thrombus resolution rate was 62.5% (60/96 mITT 
patients; 95% CI 52.0-72.2%) (Table II). 
The thrombus resolution rate was better in patients from Western European countries 
(68.0%, 34/50 patients) than from Eastern European countries (56.5%, 26/46 patients) (Table II). 
The thrombus resolution rate for the 80 patients who had both TEEs performed within the range 
of 3-12 weeks was 61.2% (95% CI 50.0-71.9%), i.e. similar to the 62.5% reported for the 96 
patients who had two TEEs. 
Secondary outcome measures 
X-TRA study 
There were no reports of stroke or noncentral nervous system systemic embolism during the 
treatment period and the 30-day follow-up. In addition, no patients experienced a major bleeding 
event. Nonmajor bleeding events were recorded in 5 patients (Table III). 
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Table III Stroke, non-CNS systemic embolism, bleeding, and AE rate (ITT population) 
Other outcomes Total N n with event % 
Prospective X-TRA study    
Stroke/non-CNS systemic embolism 60 0 0 
Bleeding events    
Major bleeding 60 0 0 
Nonmajor bleeding 60 5 8.3 
TEAEs 60 22 36.7 
Related TEAE 60 3 5.0 
TEAE causing premature study termination 60 3 5.0 
TEAE of special interest* 60 4 6.7 
Treatment-emergent serious adverse event 60 7 11.7 
Related treatment-emergent serious AE 60 1 1.7 
Death 60 1 1.7 
Retrospective CLOT-AF registry    
Stroke/transient ischemic attack or non-CNS 
systemic embolism
†,‡
 
156 4 2.6 
(Major) bleeding events 156 1 0.6 
Abbreviations: AE, adverse event; CNS, central nervous system; ITT, intention-to-treat; mITT, 
modified intention-to-treat; TEAE, treatment-emergent adverse event; TEE, transesophageal 
echocardiogram. 
*Events of special interest were all occult and overt bleeding events considered by the 
investigator to be serious; thrombocytopenia, including decreased platelet count; hypersensitivity 
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reactions; severe skin reactions; and severe liver injury. †3 patients had a record of 
stroke/transient ischemic attack and 1 patient a record of a non-CNS systemic embolism. 
Available patient information indicates that the events had occurred shortly after the baseline 
TEE (1 patient), or that the exact date of the event was unknown (3 patients). ‡Of the 96 patients 
in the mITT population, 2 patients (2.1%) had a record of stroke/transient ischemic attack with an 
unknown start date and 1 patient (1.0%) had a major bleeding event.  
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All patients took at least one tablet of study medication. Treatment-emergent adverse 
events (TEAEs) occurred in 36.7% of patients. TEAEs reported in more than a single patient 
were bradycardia, cardiac failure, hyperthyroidism, nausea, peripheral edema, thyroid neoplasm, 
headache, and chronic renal failure. Overall, 3 patients experienced TEAEs that were assessed 
by the investigator as related to the study drug (ear hemorrhage, gingival bleeding, and 
petechia). The drug-related treatment-emergent serious adverse event rate was 1.7%. 
CLOT-AF registry 
Stroke/noncentral nervous system systemic embolism after baseline TEE or with unknown 
start date was recorded for 4 of the 156 patients. A major bleeding event was recorded for 1 
patient who had spontaneous nonhemorrhoidal bleeding in the gastrointestinal tract (with INR 
< 2.0) (Table III). 
 
Discussion 
Current guidelines recommend VKA therapy for 3 weeks upon detection of a LA/LAA 
thrombus in patients with AF and long-term treatment for those with a residual thrombus,1 but 
existing clinical evidence supporting the use of NOACs for LA/LAA thrombus resolution is limited 
to isolated case reports or small case series (usually from single center studies).23 The X-TRA 
study is the first prospective, multicenter, interventional study examining thrombus resolution 
with a NOAC (rivaroxaban) in VKA-naïve patients or patients receiving suboptimal or ineffective 
VKA therapy (INR < 2.0). The results showed that resolved or reduced thrombus (as assessed 
centrally by blinded, independent adjudicators) was evident in 60.4% of the mITT patient 
population including 2 patients with two thrombi resolved in each case, demonstrating the 
potential of rivaroxaban in this setting.  
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In X-TRA, patients were predominantly from Eastern European countries; approximately 
three-quarters were treatment naïve or untreated, and most had persistent or permanent AF. 
This particularly reflects the gap between guideline recommendation and local practice in reality, 
which means those patients with diagnosed AF were not adequately treated with an oral 
anticoagulant as recommended. Owing to the limitations of TEE and other imaging modalities, it 
could not be confirmed whether patients had recently formed a thrombus in their LA/LAA or if 
they had an "old" thrombus at screening. 
Based on the rate of resolved/reduced thrombi after rivaroxaban treatment, and the fact that 
there were no stroke or thromboembolic events during treatment and follow-up and favorable 
safety data, rivaroxaban seems to be a treatment option for patients with nonvalvular AF or atrial 
flutter and an LA/LAA thrombus. Data from prospective studies of the other NOACs in this 
setting are currently lacking, although one prospective study with dabigatran is ongoing.25 In this 
context, the X-TRA study provides important insights into a challenging clinical problem and the 
potential of NOACs for this subgroup of AF patients. 
It should be noted that, in X-TRA, the duration of AF or atrial flutter was not recorded. It 
might be the case that the longer patients had AF for, the higher possibility they had “old” 
LA/LAA thrombi (especially if they were not treated with an oral anticoagulant as recommended). 
In the X-TRA study, 76.6% of patients had persistent or permanent AF and 76.7% had no prior 
use of an oral anticoagulant. Therefore, some patients might have had “old” LA/LAA thrombi 
instead of a newly formed thrombus. These may be part of the reasons for the relatively lower 
than expected resolution rate observed in X-TRA (e.g. >80%).23 However, in one prospective 
and serial study, the LAA thrombus resolution rates were 16% at 1 month, 42% at 3 months, and 
56% at 12 months.26 This finding provides encouragement that residual thrombi might be 
resolved with continuous long-term anticoagulation treatment, which is in line with guideline 
recommendations.  
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Published data on LA/LAA thrombus resolution rates after VKA therapy vary, and the 
reported resolution rate in prospective study was relatively low 26. To further understand how 
patients with nonvalvular AF or atrial flutter who had LA/LAA thrombi on a TEE were treated in 
routine practice and their outcomes, the retrospective CLOT-AF registry collected data between 
2010 and 2013 from the same 7 countries as X-TRA to reflect standard-of-care in those 
healthcare settings. The reported thrombus resolution rates were also lower than expected (e.g. 
> 80%) but still within the expected range after VKA treatment; however, approximately one-third 
of the data were missing in this retrospective registry, which limits the generalization of the data. 
Furthermore, a direct comparison of the results of X-TRA and CLOT cannot be made 
because of the nature of the studies (prospective adjudicated study vs retrospective 
nonadjudicated registry), differences in patient demographics and disease severity, as well as 
data quality (i.e. centrally adjudicated data vs hospital medical records). Thus, our results report 
descriptive observations, and no causality is implied. 
What is most important for the patients from clinical perspective? Ultimately it is about 
whether the patients are safe from major clinical events. In the X-TRa study, no stroke or 
peripheral embolism or major bleeding was reported during the 6-week treatment period and the 
30-day follow-up period. The overall reported rate for TEAEs and bleeding events was in the 
expected range observed in other phase III/IV studies of rivaroxaban27,28 and the drug-related 
treatment-emergent SAE rate was also low (1.7%). Thus no safety concerns were raised in X-
TRa.  
In conclusion, the X-TRA study showed that resolved or reduced thrombus after 
rivaroxaban treatment was evident and consistent with LA/LAA thrombus resolution with VKA 
therapy from prior retrospective observational case series and the retrospective CLOT-AF 
registry. The results suggest that rivaroxaban seems to be a potential option for the treatment of 
TEE-detected LA/LAA thrombi in patients with AF or atrial flutter. 
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Figure legends 
Figure 1 Disposition of patients. *One withdrew due to gastrointestinal bleeding and hepatic 
metastasis after 7 days of treatment, and had no baseline thrombus as adjudicated. †Female, 57 
years old, died of acute left ventricular failure, unrelated to study treatment. ‡In this retrospective 
study, this information was missing. §Female, 83 years old, died of cardiac decompensation and 
cardiac arrest 13 days after the baseline TEE. 
 
 
